Results 161 to 170 of about 1,091,889 (296)

Evolving Standards: Good Clinical Practice Insights from US FDA, MHRA UK, and Health Canada. [PDF]

Clin Pharmacol Ther
Grandinetti C, Budwal-Jagait M, Abid H, Gebbia E, Boley E, Williams L, Fisher A, Marcus L, Muldowney L, Sellers J, Wakelin-Smith J, Ayalew K.   +11 more
europepmc   +1 more source

Correction to: Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency. [PDF]

Ther Innov Regul Sci, 2022
Sellers JW, Mihaescu CM, Ayalew K, Kronstein PD, Yu B, Ning YM, Rodriguez M, Williams L, Khin NA.   +8 more
europepmc   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency. [PDF]

Ther Innov Regul Sci, 2022
Sellers JW, Mihaescu CM, Ayalew K, Kronstein PD, Yu B, Ning YM, Rodriguez M, Williams L, Khin NA.   +8 more
europepmc   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

Principles of good clinical practice in thermal rehabilitation

, 2010
Introduction. Thermal rehabilitation is a branch of Rehabilitation for which there is still a lack of randomized clinical trials. We opted to follow new research and to draft practical guidelines for thermal rehabilitation in Italy according to a ...
M. De Fabritiis, G. Gigante, S. Mariotti, MASIERO, STEFANO   +3 more
core  

Good Clinical Practice and Good Laboratory Practice

, 2009
Nathalie K. Zgheib, Stephanie L. Tomasic, Robert A. Branch   +2 more
openaire   +1 more source

Good Clinical Practice [PDF]

Journal of pharmacology & clinical research, 2019
openaire   +1 more source

A 7-Year Analysis of the U.S. FDA Good Clinical Practice Inspection Outcomes for Marketing Applications. [PDF]

Ther Innov Regul Sci
McGuire C, Sellers JW, Muldowney L.
europepmc   +1 more source

Good Clinical Practice of the Italian Society of Thalassemia and Haemoglobinopathies (SITE) for the Management of Endocrine Complications in Patients with Haemoglobinopathies. [PDF]

J Clin Med, 2022
Casale M, Baldini MI, Del Monte P, Gigante A, Grandone A, Origa R, Poggi M, Gadda F, Lai R, Marchetti M, Forni GL.   +10 more
europepmc   +1 more source